Dario Campana

This inventor holds 39 USPTO granted patents and 15 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Immunotherapy Techniques. Top assignees: National University of Singapore, St. Jude Children's Research Hospital, Nkarta, Inc.. Active years: 2008-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dario Campana. Retrieved from https://idiyas.com/inventor/dario-campana

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 39 (Patent Applications = 15)

% Patents Active = 94.9

CIPO Patents = 1 (Patent Applications = 43)

EPO Patents = 4 (Patent Applications = 22)

Average Co-Inventor Count = 2.4

ph-index = 10

Forward Citations = 797(Granted Patents)

Location History:

Germantown, TN (US) (2008 - 2013)
Kent Vale, SG (2017)
Singapore, SG (2016 - 2024)

Company Filing History:

30 out of 851

National University of Singapore

patents

23 out of 281

St. Jude Children's Research Hospital

Unum Therapeutics Inc.

patent

where one patent can have more than one assignee

Years Active: 2008-2026

Loading Chart...

Areas of Expertise:

Chimeric Receptors

Natural Killer Cells

T Cell Malignancies

Cytokine Neutralization

Immune Cell Expansion

Therapeutic Efficacy

Cell Therapy

Membrane-Bound Interleukin

Cancer Treatment

Acute Leukemia

39 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12698476 - CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR USE IN CELL THERAPY AGAINST CANCER AND INFECTIOUS DISEASE (2026-08-04),

2. 12486514 - A Method to Specifically Stimulate Survival and Expansion of Genetically-Modified Immune Cells (2025-12-02),

3. 12479914 - T CELL RECEPTOR-DEFICIENT CHIMERIC ANTIGEN RECEPTOR T-CELLS AND METHODS OF USE THEREOF (2025-11-25),

4. 12441787 - Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells (2025-10-14),

5. 12404492 - Methods for enhancing efficacy of therapeutic immune cells (2025-09-02),

6. 12404491 - Methods for enhancing efficacy of therapeutic immune cells (2025-09-02),

7. 12351617 - Immune cells comprising truncated NKG2D chimeric receptors (2025-07-08),

8. 12264335 - Natural killer cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof (2025-04-01),

9. 12258381 - Activating chimeric receptors and uses thereof in natural killer cell immunotherapy (2025-03-25),

10. 12129485 - Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies (2024-10-29),

11. 11945865 - Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies (2024-04-02),

12. 11896616 - Stimulatory cell lines for ex vivo expansion and activation of natural killer cells (2024-02-13),

13. 11873512 - Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease (2024-01-16),

14. 11709164 - Approach for universal monitoring of minimal residual disease in acute myeloid leukemia (2023-07-25),

15. 11679132 - Methods for enhancing efficacy of therapeutic immune cells (2023-06-20),

Title: Dario Campana: A Pioneer in Immunotherapy Innovations

Introduction: Dario Campana, located in Singapore, is a prominent inventor renowned for his remarkable contributions to the field of immunotherapy, particularly in developing novel therapies for T-cell malignancies. With an impressive portfolio of 30 patents, Campana is a leading figure in advancing cancer treatment through innovative research.

Latest Patents: Among his latest patents, two notable inventions stand out. The first, titled "Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies," focuses on engineered immune cells that include an anti-CD2 protein expression blocker (PEBL) and an anti-CD2 chimeric antigen receptor (CAR). This invention is significant as it describes methods for utilizing such engineered cells in cancer therapies, particularly through the blockade of CD2 surface expression.

The second patent, "Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies," presents compositions that involve an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker. This invention also provides methods for employing these compositions in cancer therapy, further showcasing Campana's dedication to improving cancer treatment options.

Career Highlights: Dario Campana has made significant strides in his career, working with esteemed institutions such as St. Jude Children's Research Hospital and the National University of Singapore. His work in these prominent research settings has not only advanced his expertise but also played a critical role in the evolution of immunotherapy strategies.

Collaborations: Campana has collaborated with various talented individuals in the field, including notable coworkers Chihaya Imai and Yu-Hsiang Chang. These partnerships have facilitated the exchange of ideas and research techniques, reinforcing the innovative outcomes of his projects.

Conclusion: Dario Campana exemplifies the spirit of innovation and dedication to medical research. With a focus on immunotherapy for T-cell malignancies and a robust patent portfolio, his contributions have the potential to make a significant impact in cancer treatment. His ongoing research and collaborations continue to pave the way for new breakthroughs in the battle against cancer.

Profile summary based on public USPTO records.